4 completed, 3 unknown, 1 recruiting, 1 terminated. 9 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Unknown 3, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 1, Recruiting 1, Terminated 1, Unknown 1 |
Follow Comparator: new trials by email Literature Review of Comparator trials Research Report on Comparator
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 61Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET) 61Cu-NODAGA-LM3, Comparator - Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | University Hospital, Basel, Switzerland | 27 | 2025-02-05 | 2025-05-30 |
| Brivaracetam Bioequivalence Assessment Briveka ® 100 mg, Briviact® 100 mg - Bioequivalence Study in Healthy Subjects | Phase 1 | Completed | Zodiac Produtos Farmaceuticos S.A. | 28 | 2024-08-09 | 2026-09-02 |
| Application and Research of Mesenchymal Stem Cells in Alleviating Severe Development of COVID-19 Infection Umbilical cord mesenchymal stem cells implantation, Comparator - COVID-19 | Phase 1 / Phase 2 | Unknown | Hebei Medical University | 20 | 2023-01-28 | 2023-02-23 |
| The Safety and Efficacy of MoodElite T-4003-1 on Improving Mood in a Healthy Adult Population With Mild to Moderate Depressive Symptoms Not Eligible for Therapeutic Intervention MoodElite T-4003-1, Comparator, Placebo - Mood | Phase 1 / Phase 2 | Completed | Chenland Nutritionals Inc. | 44 | 2022-03-24 | 2023-03-22 |
| Study to Investigate the Pharmacodynamic Effects of IP2015 in Healthy Male Subjects Using the Intradermal Capsaicin Model IP2015, dose 1, IP2015, dose 2, Placebo - Pain | Phase 1 | Unknown | Initiator Pharma | 24 | 2022-01-05 | 2022-01-06 |
| The Safety and PK Characteristics of the Co-administration of JLP-2002 and Comparator in Healthy Volunteers JLP-2002, Comparator - Overactive Bladder(OAB) | Phase 1 | Completed | Jeil Pharmaceutical Co., Ltd. | 42 | 2021-03-13 | 2021-06-14 |
| Phase 1 to Evaluate the Safety and Pharmacokinetic Characteristics of Fixed-dose Combination of YYC506 YYC506-T and YYC506-A (phase 1), YYC506 (phase 1), YYC506-T and YYC506-A (phase 2) - Dyslipidemias | Phase 1 | Unknown | Yooyoung Pharmaceutical Co., Ltd. | 60 | 2021-01-07 | 2021-05-05 |
| Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers Treatment 1 (EG-HZ-001), Treatment 2 (EG-HZ-002), Treatment 3 (EG-HZ-003) - Prevention of Herpes Zoster (HZ) | Phase 1 | Completed | EyeGene Inc. | 40 | 2020-02-24 | 2021-02-08 |
| GoldenCareTM for the Treatment of Bacterial Vaginosis GoldenCare, Metronidazole - Bacterial Vaginosis | Phase 1 / Phase 2 | Terminated | CDA Research Group, Inc. | 8 | 2013-02-01 | 2015-02-03 |
COVID-19 (1) · Dyslipidemias (1) · Neuroendocrine Tumors (1) · Pain (1) · Urinary Bladder, Overactive (1) · Vaginosis, Bacterial (1)
CDA Research Group, Inc. (1) · Chenland Nutritionals Inc. (1) · EyeGene Inc. (1) · Hebei Medical University (1) · Initiator Pharma (1) · Jeil Pharmaceutical Co., Ltd. (1) · University Hospital, Basel, Switzerland (1) · Yooyoung Pharmaceutical Co., Ltd. (1) · Zodiac Produtos Farmaceuticos S.A. (1)
South Korea (2) · Australia (1) · Brazil (1) · Canada (1) · China (1) · Switzerland (1) · United States (1)
Ashwin Chatwani, MD (1) · Baoyong Yan, Master (1) · David Crowley, MD (1) · Ding Yu, Master (1) · Gang Liu, Master (1) · Guillaume Nicolas, Dr. (1) · Jiawei Yang, Postgraduate (1) · Le Wang, Master (1) · Min Kyu Park, PhD (1) · Mingqi Zheng, Master (1) · Quanhai Li, Master (1) · Sandra Connell, MD (1) · Tianshuo Li, Postgraduate (1) · Wuzhuang Sun, Master (1) · Xianyun Wang, Doctor (1)
PMID 25329189, PMID 29859173, PMID 31978293, PMID 31986257, PMID 32085846, PMID 32257537, PMID 32811531, PMID 33514427, PMID 34750382, PMID 37781954
2023 (1)